Cancer Institute A national cancer institute
designated cancer center

George Triadafilopoulos

Publication Details

  • Barrett's esophagus: proton pump inhibitors and chemoprevention I Triadafilopoulos, G., Taddei, A., Bechi, P., Freschi, G., Ringressi, M. N., Degli'Innocenti, D. R., Castiglione, F., Masini, E., Majewski, M., Wallner, G., Sarosiek, J., Dillon, J. F., McCallum, R. C., Dvorak, K., Goldman, A., Woodland, P., Sifrim, D., Richter, J. E., Vieth, M., Neumann, H., Langner, C., Ishimura, N., Amano, Y., Felix, V. N. BLACKWELL SCIENCE PUBL. 2011: 93-113


    The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.

    View details for DOI 10.1111/j.1749-6632.2011.06047.x

    View details for Web of Science ID 000301188400007

    View details for PubMedID 21950809

Stanford Medicine Resources:

Footer Links: